GleamWall
中文EN

IART INTEGRA LIFESCIENCES HOLDINGS CORP

Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 917520 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY0.8%
TTM net income YoY102.6%
TTM EPS YoY102.6%
Revenue 3-yr CAGR2.4%
Net income 3-yr CAGR-49.5%

Margins

Gross margin52.4%
Operating margin4.4%
Net margin0.8%
FCF margin5.2%
EBITDA margin—

Returns

ROE1.2%
ROA0.4%
ROIC (approx.)2.8%
Asset turnover0.46x

Leverage & solvency

Liabilities / assets69.6%
Debt / equity0.65x
Current ratio3.62x
Interest coverage0.79x

Cash quality & payout

Operating cash flow / net income10.79x
Accruals ratio-3.6%
Payout ratio—
Capex / revenue3.3%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$411.18M$418.76M$391.92M$434.93M$402.06M$415.61M$382.65M$442.65M
Cost of revenue$201.32M$199.02M$174.94M$214.06M$195.07M$206.27M$188.22M$193.57M
Gross profit$209.87M$219.74M$216.98M$220.87M$206.99M$209.33M$194.43M$249.07M
R&D expense$21.90M$24.25M$23.50M$24.79M$22.46M$27.00M$24.73M$31.21M
SG&A expense$165.31M$172.44M$178.24M$169.27M$169.05M$179.89M$181.50M$178.52M
Operating income$18.90M$19.29M$11.47M$23.04M$11.76M-$512.67M-$15.50M$35.63M
Interest expense$22.96M$22.99M$22.46M$23.67M$22.73M$21.04M$18.82M$18.98M
Pretax income$15.66M$4.74M-$2.41M$4.31M-$6.82M-$530.95M-$30.04M$22.54M
Income tax$812,000$262,000$2.21M$6.01M-$1.42M-$46.88M-$4.74M$3.11M
Net income$14.85M$4.48M-$4.62M-$1.70M-$5.40M-$484.07M-$25.29M$19.43M
EPS (basic)0.190.06-0.06—-0.07-6.31-0.33—
EPS (diluted)0.190.06-0.06—-0.07-6.31-0.33—
Weighted avg. shares (diluted)78.58M78.17M76.95M—76.75M76.69M76.46M—
Balance sheet
Cash & equivalents$252.26M$214.41M$236.81M$235.05M$232.19M$217.91M$239.10M$246.38M
Short-term investments$59.67M$59.67M$28.69M$28.69M$35.69M$35.69M$34.19M$27.19M
Receivables$248.99M$267.19M$264.41M$278.85M$262.16M$284.51M$252.45M$272.37M
Inventory$464.45M$492.00M$495.04M$492.74M$489.11M$465.13M$445.42M$429.09M
Current assets$1.19B$1.19B$1.17B$1.16B$1.14B$1.14B$1.11B$1.08B
PP&E, net$441.14M$446.20M$446.88M$444.33M$437.37M$434.82M$422.91M$405.72M
Goodwill$607.83M$611.14M$613.25M$615.16M$615.20M$616.43M$1.11B$1.10B
Intangibles$1.04B$1.08B$1.11B$1.13B$1.16B$1.19B$1.19B$1.21B
Total assets$3.51B$3.56B$3.58B$3.60B$3.65B$3.67B$4.05B$4.04B
Current liabilities$329.00M$330.88M$346.85M$455.98M$364.05M$929.81M$918.45M$922.13M
Long-term debt$697.50M$707.19M$716.88M$726.56M$736.25M$745.94M$755.62M$760.47M
Total debt$697.50M$707.19M$716.88M$726.56M$736.25M$745.94M$755.62M$760.47M
Total liabilities$2.44B$2.52B$2.54B$2.56B$2.61B$2.63B$2.53B$2.49B
Shareholders' equity$1.07B$1.04B$1.04B$1.04B$1.04B$1.04B$1.52B$1.55B
Net debt$445.24M$492.77M$480.07M$491.51M$504.06M$528.02M$516.52M$514.09M
Cash flow statement
Operating cash flow$95.98M$22.80M$9.80M$11.82M$40.91M$8.92M-$11.26M$50.74M
Capital expenditure$10.25M$12.31M$14.85M$17.21M$15.16M$20.15M$28.92M$29.60M
Free cash flow$85.73M$10.49M-$5.04M-$5.40M$25.75M-$11.23M-$40.18M$21.14M
Investing cash flow-$10.25M-$43.28M-$14.85M-$34.91M-$15.59M-$21.65M-$35.92M-$4.25M
Financing cash flow-$46.29M-$818,000$8.30M$24.34M-$10.24M-$21.14M$35.38M-$7.15M
Stock-based compensation$2.90M$5.84M$5.17M$5.84M$5.58M$5.29M$1.87M$7.15M
Share buybacks$0——$0$0——$2.47M

Free plan shows the latest 8 periods; Pro shows all 70 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.